Editas Medicine Inc (EDIT) saw its loss widen to $31.10 million, or $0.85 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $17.74 million, or $0.80 a share. Revenue during the quarter dropped 15.28 percent to $0.68 million from $0.80 million in the previous year period.
Operating loss for the quarter was $30.63 million, compared with an operating loss of $17.84 million in the previous year period.
“We made outstanding progress this quarter building our business for the long term, including forming a strategic alliance with Allergan in ocular diseases, cementing our unmatched intellectual property position with a favorable USPTO decision, and doubling our cash runway,” said Katrine Bosley, president and chief executive officer of Editas Medicine. “These achievements represent significant strides forward in positioning Editas Medicine to execute our vision to build a company that pioneers a broad new category of genomic medicines.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]